Alzheimer's disease is the most common form of dementia, accounting for 60% -80% of cases according to the World Health Organization (WHO). It involves a deterioration of memory, intellect, behavior and ability to perform activities of daily life. This disease has an impact, not only on those who suffer from it, but also family and caregivers who are subjected to great physical, emotional and economic stress.
It is currently estimated more than 35 million people worldwide suffer from Alzheimer's, and this figure is continuing to grow. The WHO estimates that, by 2030, the number of detected cases will have doubled.
Grifols and Alzheimer's
Since 2004, we have led a broad range of research initiatives on Alzheimer's.
The AMBAR hypothesis
AMBAR is an innovative treatment proposal aimed at slowing the progression of Alzheimer's disease through periodic plasma exchange.
AMBAR is an international and multicenter clinical trial designed by Grifols in collaboration with Fundació ACE in Barcelona, Spain; and the Alzheimer Disease Research Center in Pittsburgh, PA, U.S.
The new results of AMBAR, an innovative treatment approach for Alzheimer's disease (AD) using plasma science, show that both mild and moderate patients improve after treatment.